Anti-fibrotic therapy: Lost in translation?

Journal of Hepatology

Volumn 56, Issue SUPPL. 1, 2012, Pages

  Schuppan, Detlef ^a,b   Pinzani, Massimo ^c,d  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Anti fibrotic; Cirrhosis; Collagen; Fibrogenesis; Fibrosis; HBV; HCV; Imaging; Inflammation; Liver; Microparticle; MicroRNA; Mouse; NASH; Noninvasive; PBC; Progression; Proteomics; Regression; Serum marker; Stellate cell; Treatment; Trial

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; AZATHIOPRINE; BIOLOGICAL MARKER; COLCHICINE; CORTICOSTEROID; FARGLITAZAR; GAMMA INTERFERON; GLITAZONE DERIVATIVE; INTERLEUKIN 10; LAMIVUDINE; LOSARTAN; METFORMIN; MICRORNA; PIOGLITAZONE; PLACEBO; RIBAVIRIN; ROSIGLITAZONE; URSODEOXYCHOLIC ACID;

ALCOHOL ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BARIATRIC SURGERY; CHOLESTASIS; CHRONIC LIVER DISEASE; DECOMPRESSION SURGERY; DISEASE COURSE; DISEASE MARKER; DRUG SCREENING; DRUG TARGETING; ELASTOGRAPHY; EXOSOME; FIBROGENESIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MORBIDITY; MORTALITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSCRIPTOMICS;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; HUMANS; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84856461322     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(12)60008-7     Document Type: Article

References (72)

1. M Pinzani, J Macias-Barragan Update on the pathophysiology of liver fibrosis Expert Rev Gastroenterol Hepatol 4 2010 459 472
2. SL Friedman Mechanisms of hepatic fibrogenesis Gastroenterology 134 2008 1655 1669 (Pubitemid 351615417)
3. D Schuppan, NH Afdhal Lancet Seminars: Liver cirrhosis Lancet 371 2008 838 851
4. SL Friedman, MB Bansal Reversal of hepatic fibrosis - Fact or fantasy? Hepatology 43 2006 S82 S88
5. WJ Powell Jr, G Klatskin Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease Am J Med 44 1968 406 420
6. YO Kweon, ZD Goodman, JL Dienstag, ER Schiff, NA Brown, E Burchardt et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B J Hepatol 35 2001 749 755 (Pubitemid 34717666)
7. YF Liaw, JJ Sung, WC Chow, G Farrell, CZ Lee, H Yuen et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
8. T Poynard, J McHutchison, M Manns, C Trepo, K Lindsay, Z Goodman et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313 (Pubitemid 34465173)
9. AM Di Bisceglie, ML Shiffman, GT Everson, KL Lindsay, JE Everhart, EC Wright et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
10. JF Dufour, R DeLellis, MM Kaplan Reversibility of hepatic fibrosis in autoimmune hepatitis Ann Intern Med 127 1997 981 985 (Pubitemid 27516609)
11. AR Ferreira, ML Roquete, NH Toppa, LP de Castro, ED Fagundes, FJ Penna Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis J Pediatr Gastroenterol Nutr 46 2008 65 70
12. AL Fracanzani, S Fargion, R Romano, D Conte, A Piperno, R D'Alba et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis Hepatology 22 1995 1127 1131
13. RE Poupon, B Balkau, E Eschwge, R Poupon A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group N Engl J Med 324 1991 1548 1554
14. C Corpechot, F Carrat, AM Bonnand, RE Poupon, R Poupon The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis Hepatology 32 2000 1196 1199
15. P Hammel, A Couvelard, D O'Toole, A Ratouis, A Sauvanet, JF Fléjou et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct N Engl J Med 344 2001 418 423 (Pubitemid 32128674)
16. R Belfort, SA Harrison, K Brown, C Darland, J Finch, J Hardies et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 2006 2297 2307 (Pubitemid 44837778)
17. GP Aithal, JA Thomas, PV Kaye, A Lawson, SD Ryder, I Spendlove, AS Austin, JG Freeman, L Morgan, J Webber Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis Gastroenterology 135 2008 1176 1184
18. V Ratziu, F Charlotte, C Bernhardt, P Giral, M Halbron, G Lenaour et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial Hepatology 51 2010 445 453
19. AJ Sanyal, N Chalasani, KV Kowdley, A McCullough, AM Diehl, NM Bass et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
20. JE Lavine, JB Schwimmer, ML Van Natta, JP Molleston, KF Murray, P Rosenthal et al. Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial JAMA 305 2011 1659 1668
21. NC Chavez-Tapia, FI Tellez-Avila, T Barrientos-Gutierrez, N Mendez-Sanchez, J Lizardi-Cervera, M Uribe Bariatric surgery for non-alcoholic steatohepatitis in obese patients Cochrane Database Syst Rev 1 2010 CD007340
22. R Olsson, KM Boberg, OS de Muckadell, S Lindgren, R Hultcrantz, G Folvik et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study Gastroenterology 129 2005 1464 1472 (Pubitemid 41597389)
23. TJ Weismüller, J Wedemeyer, S Kubicka, CP Strassburg, MP Manns The challenges in primary sclerosing cholangitis-aetiopathogenesis, autoimmunity, management and malignancy J Hepatol 48 Suppl 1 2008 S38 S57
24. A Rambaldi, C Gluud Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis Cochrane Database Syst Rev 2 2005 CD002148
25. DR Nelson, Z Tu, C Soldevila-Pico, M Abdelmalek, H Zhu, YL Xu et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect Hepatology 38 2003 859 868 (Pubitemid 37221669)
26. PJ Pockros, L Jeffers, N Afdhal, ZD Goodman, D Nelson, RG Gish et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis Hepatology 45 2007 569 578 (Pubitemid 46450609)
27. J McHutchison, Z Goodman, K Patel, H Makhlouf, M Rodriguez-Torres, M Shiffman et al. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection Gastroenterology 138 2010 1365 1373
28. J Colmenero, R Bataller, P Sancho-Bru, M Domínguez, M Moreno, X Forns et al. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C Am J Physiol Gastrointest Liver Physiol 297 2009 G726 G734
29. Y Popov, D Schuppan Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies Hepatology 50 2009 1294 1306
30. M Parola, M Pinzani Hepatic wound repair Fibrogenesis Tissue Repair 2 2009 4
31. S De Minicis, E Seki, H Uchinami, J Kluwe, Y Zhang, DA Brenner, RF Schwabe Gene expression profiles during hepatic stellate cell activation in culture and in vivo Gastroenterology 132 2007 1937 1946 (Pubitemid 46677935)
32. A Mallat, AM Preaux, S Blazejewski, J Rosenbaum, D Dhumeaux, P Mavier Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture Hepatology 21 1995 1003 1010
33. I Fernández, JC Meneu, F Colina, I García, R Muñoz, G Castellano et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation Liver Transpl 12 2006 1805 1812 (Pubitemid 44911807)
34. AM Di Bisceglie, ML Shiffman, GT Everson, KL Lindsay, JE Everhart, EC Wright HALT-C Trial Investigators Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
35. K Poelstra, D Schuppan Targeted therapy of liver fibrosis/cirrhosis and its complications J Hepatol 2011 May 8 [Epub ahead of print].
36. L Beljaars, DK Meijer, K Poelstra Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis Front Biosci 7 2002 e214 e222
37. M Van Beuge, J Prakash, M Lacombe, R Gosens, E Post, C Reker-Smit et al. Reduction of fibrogenesis by selective delivery of a Rho-kinase inhibitor to hepatic stellate cells in mice J Pharmacol Exp Ther 2011 Mar 7
38. R Bansal, J Prakash, E Post, L Beljaars, D Schuppan, K Poelstra A novel engineered targeted interferon gamma blocks hepatic fibrogenesis in mice Hepatology 2011 10.1002/hep.24395
39. BK Abu Dayyeh, M Yang, JL Dienstag, RT Chung The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort Dig Dis Sci 56 2011 564 568
40. P Fickert, A Fuchsbichler, M Wagner, G Zollner, A Kaser, H Tilg et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice Gastroenterology 127 2004 261 274 (Pubitemid 38962293)
41. -/-mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes J Hepatol 43 2005 1045 1054 (Pubitemid 41627991)
42. Y Popov, E Patsenker, M Bauer, E Niedobitek, A Schulze-Krebs, D Schuppan Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB J Biol Chem 281 2006 15090 15098 (Pubitemid 43855098)
43. Y Popov, DY Sverdlov, AK Sharma, KR Bhaskar, S Li, TL Freitag et al. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice Gastroenterology 140 2011 1642 1652
44. N Yilmaz, ML Shiffman, RT Stravitz, RK Sterling, VA Luketic, AJ Sanyal et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation Liver Transpl 13 2007 975 983 (Pubitemid 47163189)
45. H Huang, ML Shiffman, RC Cheung, TJ Layden, S Friedman, OT Abar et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C Gastroenterology 130 2006 1679 1687 (Pubitemid 43668836)
46. M Marcolongo, B Young, F Dal Pero, G Fattovich, L Peraro, M Guido, G Sebastiani, G Pal, A Alberti A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C Hepatology 50 2009 1038 1044
47. M Pinzani, K Rombouts Liver fibrosis: from the bench to clinical targets Dig Liver Dis 36 2004 231 342
48. P Bonnard, FX Lescure, C Amiel, JB Guiard-Schmid, P Callard, S Gharakhanian et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count Journal of Viral Hepatitis 14 2007 806 811 (Pubitemid 47561586)
49. J Macías, J Berenguer, MA Japón, JA Girón, A Rivero, LF López-Cortés et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus Hepatology 50 2009 1056 1063
50. M Fernández, D Semela, J Bruix, I Colle, M Pinzani, J Bosch Angiogenesis in liver disease J Hepatol 50 2009 604 620
51. Y Popov, DY Sverdlov, KR Bhaskar, AK Sharma, G Millonig, E Patsenker et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis Am J Physiol Gastrointest Liver Physiol 298 2010 G323 G334
52. S Ricard-Blum, S Bresson-Hadni, DA Vuitton, G Ville, JA Grimaud Hydroxypyridinium collagen cross-links in human liver fibrosis: study of alveolar echinococcosis Hepatology 15 1992 599 602
53. A Hayasaka, S Ilda, N Suzuki, F Kondo, M Miyazaki, H Yonemitsu Pyridinoline collagen cross-links in patients with chronic viral hepatitis and cirrhosis J Hepatol 24 1996 692 698 (Pubitemid 26226665)
54. R Issa, X Zhou, CM Constandinou, J Fallowfield, H Millward-Sadler, MD Gaca, E Sands et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking Gastroenterology 126 2004 1795 1808 (Pubitemid 38736345)
55. GL Davis, MJ Alter, H El-Serag, T Poynard, LW Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
56. L Castera, M Pinzani Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 59 2010 861 866
57. MJ Mayo, J Parkes, B Adams-Huet, B Combes, AS Mills, RS Markin et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay Hepatology 48 2008 1549 1557
58. RJ Fontana, JL Dienstag, HL Bonkovsky, RK Sterling, D Naishadham, ZD Goodman HALT-C Trial Group Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C Gut 59 2010 1401 1409
59. J Parkes, P Roderick, S Harris, C Day, D Mutimer, J Collier et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease Gut 59 2010 1245 1251
60. J Vergniol, J Foucher, E Terrebonne, PH Bernard, BL Bail, W Merrouche et al. Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients with Chronic Hepatitis C Gastroenterology 2011 Mar 2
61. L Castéra, G Sebastiani, B Le Bail, V de Lédinghen, P Couzigou, A Alberti Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C J Hepatol 52 2010 191 198
62. CJ Guo, Q Pan, DG Li, H Sun, BW Liu miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis J Hepatol 50 2009 766 778
63. T Ogawa, M Iizuka, Y Sekiya, K Yoshizato, K Ikeda, N Kawada Suppression of type I collagen production by microRNA-29b in cultured human stellate cells Biochem Biophys Res Commun 391 2010 316 321
64. X Jiang, E Tsitsiou, SE Herrick, MA Lindsay MicroRNAs and the regulation of fibrosis FEBS J 277 2010 2015 2021
65. C Roderburg, GW Urban, K Bettermann, M Vucur, H Zimmermann, S Schmidt et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis Hepatology 53 2011 209 218
66. Y Murakami, H Toyoda, M Tanaka, M Kuroda, Y Harada, F Matsuda et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families PLoS One 6 2011 e16081
67. Y Sekiya, T Ogawa, K Yoshizato, K Ikeda, N Kawada Suppression of hepatic stellate cell activation by microRNA-29b Biochem Biophys Res Commun 2011 Jul 21 [Epub ahead of print].
68. M Kornek, Y Popov, TA Libermann, NH Afdhal, D Schuppan Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells Hepatology 53 2011 230 242
69. DA Aguirre, CA Behling, E Alpert, TI Hassanein, CB Sirlin Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging Radiology 239 2006 425 437
70. SC Faria, K Ganesan, I Mwangi, M Shiehmorteza, B Viamonte, S Mazhar et al. MR imaging of liver fibrosis: current state of the art Radiographics 29 2009 1615 1635
71. B Wang, BM Dolinski, N Kikuchi, DR Leone, MG Peters, PH Weinreb et al. Role of alphavbeta6 integrin in acute biliary fibrosis Hepatology 46 2007 1404 1412 (Pubitemid 350155522)
72. E Patsenker, Y Popov, F Stickel, A Jonczyk, SL Goodman, D Schuppan Inhibition of integrin alphavbeta6 on bile duct epithelial cells blocks TGF beta activation and retards progression of biliary fibrosis Gastroenterology 135 2008 660 670